Overview

A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

Status:
Recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

This is a prospective, multi-center, single arm study assessing the efficacy and safety of durvalumab given concurrently with platinum-based CRT (durvalumab + SoC CRT) in patients with locally advanced, unresectable NSCLC (Stage III).

Phase:

Phase 2

Details

Lead Sponsor:

Shandong Cancer Hospital and Institute

Treatments:

Carboplatin
Cisplatin
Durvalumab
Etoposide
Paclitaxel
Pemetrexed